Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Drug:
Detox-B adjuvant
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Immunotherapy with an Allogeneic Melanoma Vaccine plus Interferon Alfa vs Interferon Alfa Alone in Patients with Metastatic Malignant Melanoma (Summary Last Modified 04/2000)
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CORIXA-2885-14
, RIR-2885-14, YALE-HIC-8666, NCI-V96-0883, NCT00002767
2.
Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001)
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BIOMIRA-STn-BR-104
, NCI-V98-1489, NCT00003638
3.
Phase III Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate-Thickness, Node-Negative Malignant Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-9035
4.
Phase III Randomized Study of Melacine (Melanoma Cell Lysate Vaccine) vs Chemotherapy with DTIC/CDDP/BCNU/TMX in Patients with Disseminated Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
16 and over
Sponsor:
Protocol IDs:
RIR-91CO28-CC
, NCI-V92-0019, NCI-V92-0102
5.
Phase I/II Study of Photodynamic Therapy With Verteporfin and Detox-B Adjuvant in Patients With Stage III or IV Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
QLT-VFI-PDV-01
, QLT-PHO-VFI-PDV-01, NCT00007969
6.
Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
UNMC-04094
, NCI-V94-0589
7.
Phase II Pilot Study of Vaccination with the Ganglioside GM2 Covalently Attached to Keyhole Limpet Hemocyanin plus the Immunological Adjuvant Detox in Patients with Completely Resected Stage III/IV Malignant Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
any age
Sponsor:
Protocol IDs:
MSKCC-91012
, NCI-V91-0043
8.
Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
any age
Sponsor:
Protocol IDs:
MSKCC-91095
, NCI-V91-0167
9.
Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-94-C-0096D
, NCI-T93-0152N, T93-0152, NCT00019006
10.
Phase I Study of IL-2/CTX and Autologous Tumor Cell Vaccines in the Treatment of Metastatic Renal Carcinoma and Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
URCC-3788M
, NCI-T88-0151D, T88-0151
11.
Phase I Study of Adjuvant IL-1A Immunotherapy with an Allogeneic Colon Cancer Vaccine for Dukes' D Colon or Rectal Cancer (Summary Last Modified 06/97)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
21 to 100
Sponsor:
NCI
Protocol IDs:
URCC-4290M
, NCI-T91-0094D, T91-0094
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute